English
Chinese
Cart
This product is not clubbable with other items in cart. Please remove this or other items to proceed further.
Deleting
No Items In Cart
SmartDose® 3.5 On-Body Delivery System
Proud to support our partners with our SmartDose® technology:
Since 2010, West has invested in development of our SmartDose® technology scaling it to meet various application and delivery volume needs.
Patient-Centric
Flexible Technology
Additional Support
Downloadable Resources
SmartDose® is a registered trademark of West Pharma. Services IL, Ltd., a subsidiary of West Pharmaceutical Services, Inc.
Flurotec® is a registered trademark of Daikyo Seiko, Ltd.
SelfDose™ is a trademark of West Pharmaceutical Services, Inc.
The logos above are the property of their respective owners and are used with permission.
Related Blogs
March 12, 2021
Is home-based administration possible? Exploring the intravenous to subcutaneous transition in cancer treatments.
Imagine self-administered cancer treatments in the comfort of a patient’s home. How close are we to making this a reality? During this unprecedented time, immuno-compromised patients can benefit from receiving a self-administered, home-based treatment option. One major factor into making home-based cancer treatment a reality is a focus on shifting the route of administration from intravenous to subcutaneous delivery. Due to an emphasis on patient involvement in shared decision making for health care policy and medical approaches, understanding the intravenous to subcutaneous transition in medical injections has garnered increased importance. If therapeutic efficacy is not compromised, the less invasive nature and convenience of subcutaneous injections is often the preferred route of administration.1-2,4-6
June 17, 2020
Improving the Patient Experience without Sacrificing Quality of Care
The impact of a cancer diagnosis can be stressful. Questions such as “how will I tell my family?”, “how will I afford to pay my bills?”, “will I ever work again?” and even “will I survive?” are at the forefront of the patient’s mind as they process their diagnosis and begin treatment. So, how can the patient experience with treatment be supported? By offering the best quality of care.
August 14, 2020
How the FDA PFDD initiative is bringing the patients voice earlier into drug development
In the biologics space, there are clear trends toward higher delivery volumes, less frequent dosing, and the conversion from intravenous to subcutaneous delivery. This is driving demand for wearable technologies. Read more below about the FDA’s Patient-Focused Drug Development (PFDD) Initiative and how these findings can enable more insightful patient offerings.
March 12, 2021
Is home-based administration possible? Exploring the intravenous to subcutaneous transition in cancer treatments.
Imagine self-administered cancer treatments in the comfort of a patient’s home. How close are we to making this a reality? During this unprecedented time, immuno-compromised patients can benefit from receiving a self-administered, home-based treatment option. One major factor into making home-based cancer treatment a reality is a focus on shifting the route of administration from intravenous to subcutaneous delivery. Due to an emphasis on patient involvement in shared decision making for health care policy and medical approaches, understanding the intravenous to subcutaneous transition in medical injections has garnered increased importance. If therapeutic efficacy is not compromised, the less invasive nature and convenience of subcutaneous injections is often the preferred route of administration.1-2,4-6
June 17, 2020
Improving the Patient Experience without Sacrificing Quality of Care
The impact of a cancer diagnosis can be stressful. Questions such as “how will I tell my family?”, “how will I afford to pay my bills?”, “will I ever work again?” and even “will I survive?” are at the forefront of the patient’s mind as they process their diagnosis and begin treatment. So, how can the patient experience with treatment be supported? By offering the best quality of care.
August 14, 2020
How the FDA PFDD initiative is bringing the patients voice earlier into drug development
In the biologics space, there are clear trends toward higher delivery volumes, less frequent dosing, and the conversion from intravenous to subcutaneous delivery. This is driving demand for wearable technologies. Read more below about the FDA’s Patient-Focused Drug Development (PFDD) Initiative and how these findings can enable more insightful patient offerings.
